Affiliation:
1. , Hasanuddin University, , Indonesia
2. , , Hasanuddin University, , Indonesia
Abstract
BACKGROUND: Increased plasma aldehyde dehydrogenase 1 (ALDH1) levels have been proposed to predict cancer chemoresistance. However, studies have reported inconsistent results, depending on the type of cancer cells used. OBJECTIVE: This study aimed to investigate the correlation between plasma levels of ALDH1 and chemotherapy responses to the taxane–adriamycin–cyclophosphamide (TAC) regimen in breast cancer patients. METHODS: Thirty breast cancer patients who underwent chemotherapy using the TAC regimen were included in this study. Blood sampling was performed before chemotherapy was initiated and after the first and third cycles of chemotherapy administration. After 3 cycles of chemotherapy, patients were categorized as non-responsive if the tumor size was reduced <30%, if the tumor size remained the same or increased, or if any new tumors were discovered. Patients were defined as responsive after 3 cycles of chemotherapy if the tumor mass disappeared, if the tumor size was reduced by at least 30% of the initial size and if no new tumors were found. RESULTS: Among the 30 patients, only five were responsive to the TAC regimen. The clinical response to TAC was not correlated with the patient’s age, cancer grading, or tumor stage. A change in the ALDH1 levels was observed after the third cycle of TAC administration, with significantly higher ALDH1 levels observed in responsive compared with non-responsive patients (p < 0.05). CONCLUSION: The results of this study may indicate a role for ALDH1 in chemoresponsiveness, rather than chemoresistance, for the TAC regimen in breast cancer patients. Further research remains necessary to confirm this result.
Subject
Cancer Research,Oncology,General Medicine
Reference17 articles.
1. American cancer society/American society of clinical oncology breast cancer survivorship care guideline;Runowicz;CA: A Cancer Journal for Clinicians,2016
2. Neoadjuvant chemotherapy considerations in triple-negative breast cancer;McAndrew;The Journal of Targeted Therapies in Cancer,2018
3. Cost effectiveness of tac versus fac in adjuvant treatment of node-positive breast cancer;Mittmann;Current Oncology,2010
4. Cancer stem cells: Current status and evolving complexities;Visvader;Cell Stem Cell,2012
5. Cancer stem cells: Controversial or just misunderstood?;Jordan;Cell Stem Cell,2009
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献